Myeloid Growth Factor Therapy for Prophylaxis of Febrile Neutropenia in Non-Myeloid Malignancies: Appropriate Doses and Schedules

Myeloid growth factors (MGFs) are used for the prophylaxis of febrile neutropenia and maintenance of scheduled dose delivery in the treatment of patients undergoing cancer chemotherapy. To spare cost and for patient convenience, in adults MGFs are used at schedules, doses, and durations that differ from the approved prescribing information of the U.S. Food and Drug Administration. These variations include rounding doses to convenient sizes, fewer days of treatment, a shorter interval between cycles, and same-day administration with chemotherapy. Some of these variations are supported by clinical trial results and practice guidelines.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence: Betsy L. Althaus, PharmD, BCOP, UCSF National Comprehensive Cancer Center, 1600 Divisadero Street, #1712, San Francisco, CA 94115. E-mail: betsy.althaus@ucsfmedctr.org
  • 1.

    Crawford J, Althaus B, Armitage J. The NCCN Myeloid Growth Factors Clinical Practice Guidelines in Oncology, version 1, 2006. Available at: http://www.nccn.org/professionals/physician_glas/PDF/myeloid_growth.pdf. Accessed December 5, 2006.

    • Search Google Scholar
    • Export Citation
  • 2.

    Neupogen (filgrastim) [prescribing information]. Thousand Oaks, CA: Amgen; 2004.

  • 3.

    Leukine (sargramostim) [prescribing information]. Seattle, WA: Berlex; 2004.

  • 4.

    Smith TJ, Khatcheressian J, Lyman GH. Update for recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:31873205.

    • Search Google Scholar
    • Export Citation
  • 5.

    Neulasta (pegfilgrastim) [prescribing information]. Thousand Oaks, CA: Amgen; 2004.

  • 6.

    Johnston E, Crawford J, Blackwell S. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000;18:25222528.

    • Search Google Scholar
    • Export Citation
  • 7.

    Aapro MS, Cameron DA, Pettengell R. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumors. Eur J Cancer 2006;42:24332453.

    • Search Google Scholar
    • Export Citation
  • 8.

    Scott SD, Chrischilles EA, Link BK. Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy. J Manag Care Pharm 2003;9(2 suppl):1521.

    • Search Google Scholar
    • Export Citation
  • 9.

    Weycker D, Hackett J, Edelsberg JS. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother 2006;40:402407.

    • Search Google Scholar
    • Export Citation
  • 10.

    Citron ML, Berry DA, Cirrincione C. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:14311439.

    • Search Google Scholar
    • Export Citation
  • 11.

    Papaldo P, Lopez M, Marolla P. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol 2005;23:69086918.

    • Search Google Scholar
    • Export Citation
  • 12.

    Djulbegovic B, Frohlich A, Bennett CL. Acting on imperfect evidence: how much regret are we ready to accept? J Clin Oncol 2005;23:68226825.

  • 13.

    Yang BB, Hill RL, Hollifield AM. Pegfilgrastim serum concentrations on the twelfth day after dosing are unlikely to stimulate granulopoiesis: a retrospective analysis of 6 clinical trials in a variety of cancer populations. Poster presented at the 45th Annual Meeting of the American Society of Hematology; December 6–9, 2003; San Diego, California. Abstract 1918.

    • Search Google Scholar
    • Export Citation
  • 14.

    Burstein HJ, Parker LM, Keshaviah A. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol 2005;23:83408347.

    • Search Google Scholar
    • Export Citation
  • 15.

    Wolff AC, Jones RJ, Davidson NE. Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support (letter). J Clin Oncol 2006;24:23922394.

    • Search Google Scholar
    • Export Citation
  • 16.

    Brusamolino E, Rusconi C, Montalbetti L. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica 2006;91:496502.

    • Search Google Scholar
    • Export Citation
  • 17.

    Meropol NJ, Miller LL, Korn EL. Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy. J Natl Cancer Inst 1992;84:12011203.

    • Search Google Scholar
    • Export Citation
  • 18.

    Rowinsky EK, Grochow LB, Sartorius SE. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors. J Clin Oncol 1996;14:12241235.

    • Search Google Scholar
    • Export Citation
  • 19.

    Petros WP, Crawford J. Safety of concomitant use of granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor with cytotoxic chemotherapy agents. Curr Opin Hematol 1997;4:213216.

    • Search Google Scholar
    • Export Citation
  • 20.

    Weiss AJ, Lackman RD. Infusional chemotherapy combined with recombinant human granulocyte colony stimulating factor: advantages and limitations. Am J Clin Oncol 1997;20:6368.

    • Search Google Scholar
    • Export Citation
  • 21.

    Weiss AJ, Sabol J, Lackman RD. Concurrent administration of vinorelbine with recombinant human granulocyte colony-stimulating factor: an effective method of increasing dose intensity. Am J Clin Oncol 1999;22:3841.

    • Search Google Scholar
    • Export Citation
  • 22.

    Livingston RB, Ellis GK, Gralow JR. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1997;15:13951400.

    • Search Google Scholar
    • Export Citation
  • 23.

    Vance KT, Carpenter J. Same day administration of pegfilgrastim with dose dense doxorubicin in early breast cancer patients [abstract]. J Clin Oncol 2006;24(suppl 1):45s. Abstract 671.

    • Search Google Scholar
    • Export Citation
  • 24.

    Lokich J. Same day pegfilgrastim and chemotherapy. Cancer Invest 2005;23:573576.

  • 25.

    Hoffmann PS. Administration of pegfilgrastim on the same day or next day of chemotherapy [abstract]. J Clin Oncol 2005;23(suppl 1):763s. Abstract 8137.

    • Search Google Scholar
    • Export Citation
  • 26.

    Belani CP, Ramalingam A, Al-Janadi E. A randomized double-blind phase II study to evaluate same-day vs next-day administration of pegfilgrastim with carboplatin and docetaxel in patients with NSCLC [abstract]. J Clin Oncol 2006;24(suppl 1):391s. Abstract 7110.

    • Search Google Scholar
    • Export Citation
  • 27.

    Kaufman PA, Paroly W, Rinaldi D. Randomized, double-blind, phase 2 study evaluating same-day vs next-day administration of pegfilgrastim with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with early stage and advanced breast cancer [abstract]. Breast Cancer Res Treat 2004;88. Abstract 1054.

    • Search Google Scholar
    • Export Citation
  • 28.

    Martin M, Lluch A, Segui MA. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 2006;17:12051212.

    • Search Google Scholar
    • Export Citation
  • 29.

    Yardley DA, Greco FA, Burris HA. Day 1 pegfilgrastim with dose dense adjuvant chemotherapy: amelioration of docetaxel neutropenia but not that of doxorubicin/cyclophosphamide. Results from a Sarah Cannon Research Institute pilot study [abstract]. J Clin Oncol 2005;23(suppl 1):65s. Abstract 749.

    • Search Google Scholar
    • Export Citation
  • 30.

    Saven A, Schwartzberg L, Kaywin P. Randomized, double-blind, phase 2 study evaluating same-day vs. next-day administration of pegfilgrastim with R-CHOP in non-Hodgkin's lymphoma patients [abstract]. J Clin Oncol 2006;24(suppl 1):439s. Abstract 7570.

    • Search Google Scholar
    • Export Citation
  • 31.

    Lokich J. Same day pegfilgrastim and CHOP chemotherapy for non-Hodgkin's lymphoma. Am J Clin Oncol 2006;29:361363.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 115 96 2
PDF Downloads 61 53 12
EPUB Downloads 0 0 0